The dual burden of diabetes and obesity presents a formidable challenge to clinicians worldwide. As the prevalence of these interconnected conditions continues to rise, novel and effective therapeutic strategies are of paramount importance. Among the various treatments available, semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist—has emerged as a promising candidate for diabetes and obesity management. In […]